Clinical and haematological improvement induced by etidronate in a patient with idiopathic myelofibrosis and osteosclerosis

Br J Haematol. 1994 Feb;86(2):397-8. doi: 10.1111/j.1365-2141.1994.tb04750.x.

Abstract

We report a patient with agnogenic myeloid metaplasia associated with debilitating bone pain due to increased bone turnover and osteosclerosis. Treatment with etidronate at a dose of 6 mg/kg per day on alternate months resulted in a complete recovery of bone symptoms and normalization of metabolic parameters of bone turnover; unexpectedly, a sustained haematological improvement was also observed after several months of therapy, suggesting that bone marrow microenvironment improvement was able to restore a nearly normal haemopoiesis. We suggest that diphosphonate therapy may be of value in patients with AMM and increased bone turnover.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Etidronic Acid / therapeutic use*
  • Follow-Up Studies
  • Humans
  • Male
  • Osteosclerosis / drug therapy*
  • Primary Myelofibrosis / blood
  • Primary Myelofibrosis / drug therapy*

Substances

  • Etidronic Acid